Giant Cell Arteritis - Optimization of Diagnostics

Completed

• Conditions: Giant Cell Arteritis

• Registration Number: NCT05248906
• Lead Sponsor: Rigshospitalet, Denmark

Brief Summary

Giant cell arteritis - Optimization of diagnostics

Detailed Description

A prospective study. Investigating the use of ultrasound, temporal artery biopsy, biomarkers and 18F-fluorodeoxyglucose positron emission tomography-computed tomography for establishing a diagnosis of giant cell (temporal) arteritis.

Study Timeline

• Study First Submitted: 2020-11-03
• Study Start: 2021-03-19
• Status Verified: 2022-02
• Study First Submitted QC: 2022-02-10
• Study First Posted: 2022-02-21
• Primary Completion: 2024-01-01
• Study Completion: 2024-01-01
• Last Update Submitted: 2025-03-27
• Last Update Posted: 2025-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Clinical suspicion of giant cell arteritis

Meets the American College of Rheumatology Criteria:

Age at disease onset => 50 years New headache Temporal artery abnormality Elevated erythrocyte sedimentation rate >=50 mm/hour Abnomal artery biopsy

Exclusion Criteria

Active cancer Use of steroid for more than a week (the prior 6 months)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Giant cell arteritis	Week 26	Clinical verification of giant cell arteritis diagnosis as evaluated with a combination of ultrasound, biopsy and PET/CT.

Trial Locations

Locations (1)

Rigshospitalet; 🇩🇰 Copenhagen, Denmark